MYRIAD GENETICS INC (MYGN)
US62855J1043 - Common Stock
We assign a fundamental rating of 3 out of 10 to MYGN. MYGN was compared to 565 industry peers in the Biotechnology industry. MYGN may be in some trouble as it scores bad on both profitability and health. MYGN is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year MYGN was profitable.
MYGN had a negative operating cash flow in the past year.
In the past 5 years MYGN reported 4 times negative net income.
In multiple years MYGN reported negative operating cash flow during the last 5 years.
1.2 Ratios
MYGN has a Return On Assets of -14.30%. This is amongst the best in the industry. MYGN outperforms 83.10% of its industry peers.
The Return On Equity of MYGN (-20.96%) is better than 83.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.3% | ||
| ROE | -20.96% | ||
| ROIC | N/A |
ROA(3y)-11.46%
ROA(5y)-9.66%
ROE(3y)-16.36%
ROE(5y)-14.08%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MYGN's Gross Margin of 69.06% is amongst the best of the industry. MYGN outperforms 82.74% of its industry peers.
In the last couple of years the Gross Margin of MYGN has declined.
The Profit Margin and Operating Margin are not available for MYGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.06% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-2.06%
2. Health
2.1 Basic Checks
MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MYGN has more shares outstanding
The number of shares outstanding for MYGN has been increased compared to 5 years ago.
The debt/assets ratio for MYGN is higher compared to a year ago.
2.2 Solvency
MYGN has an Altman-Z score of 1.83. This is not the best score and indicates that MYGN is in the grey zone with still only limited risk for bankruptcy at the moment.
MYGN's Altman-Z score of 1.83 is fine compared to the rest of the industry. MYGN outperforms 69.75% of its industry peers.
MYGN has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
MYGN has a worse Debt to Equity ratio (0.05) than 62.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.83 |
ROIC/WACCN/A
WACC10.99%
2.3 Liquidity
MYGN has a Current Ratio of 1.96. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
MYGN has a worse Current ratio (1.96) than 75.98% of its industry peers.
MYGN has a Quick Ratio of 1.78. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
MYGN has a worse Quick ratio (1.78) than 77.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.96 | ||
| Quick Ratio | 1.78 |
3. Growth
3.1 Past
MYGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 131.82%, which is quite impressive.
The Revenue has grown by 12.15% in the past year. This is quite good.
MYGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.25% yearly.
EPS 1Y (TTM)131.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
Revenue 1Y (TTM)12.15%
Revenue growth 3Y5.66%
Revenue growth 5Y0.25%
Sales Q2Q%11.15%
3.2 Future
Based on estimates for the next years, MYGN will show a very strong growth in Earnings Per Share. The EPS will grow by 40.61% on average per year.
Based on estimates for the next years, MYGN will show a quite strong growth in Revenue. The Revenue will grow by 8.27% on average per year.
EPS Next Y147.81%
EPS Next 2Y53.9%
EPS Next 3Y48.99%
EPS Next 5Y40.61%
Revenue Next Year11.87%
Revenue Next 2Y8.17%
Revenue Next 3Y8.46%
Revenue Next 5Y8.27%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 96.43, which means the current valuation is very expensive for MYGN.
MYGN's Price/Earnings ratio is rather cheap when compared to the industry. MYGN is cheaper than 93.42% of the companies in the same industry.
MYGN is valuated expensively when we compare the Price/Earnings ratio to 27.55, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 130.87, the valuation of MYGN can be described as expensive.
Based on the Price/Forward Earnings ratio, MYGN is valued cheaper than 91.28% of the companies in the same industry.
MYGN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 24.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 96.43 | ||
| Fwd PE | 130.87 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MYGN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MYGN's earnings are expected to grow with 48.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.65
PEG (5Y)N/A
EPS Next 2Y53.9%
EPS Next 3Y48.99%
5. Dividend
5.1 Amount
MYGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MYRIAD GENETICS INC
NASDAQ:MYGN (12/26/2024, 8:00:01 PM)
After market: 13.5 0 (0%)13.5
-0.24 (-1.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners104.29%
Inst Owner Change-3.87%
Ins Owners2.22%
Ins Owner Change-2.33%
Market Cap1.23B
Analysts71.43
Price Target23.6 (74.81%)
Short Float %3.81%
Short Ratio3.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)295.74%
Min EPS beat(2)90.66%
Max EPS beat(2)500.81%
EPS beat(4)4
Avg EPS beat(4)215.82%
Min EPS beat(4)63.74%
Max EPS beat(4)500.81%
EPS beat(8)6
Avg EPS beat(8)85.25%
EPS beat(12)10
Avg EPS beat(12)87.36%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.81%
Min Revenue beat(2)1.17%
Max Revenue beat(2)2.44%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)4.97%
Revenue beat(8)5
Avg Revenue beat(8)0.03%
Revenue beat(12)7
Avg Revenue beat(12)0.18%
Revenue beat(16)11
Avg Revenue beat(16)1.86%
PT rev (1m)-23.62%
PT rev (3m)-21.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.79%
EPS NY rev (1m)21.2%
EPS NY rev (3m)37.1%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.64%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 96.43 | ||
| Fwd PE | 130.87 | ||
| P/S | 1.53 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.66 | ||
| P/tB | 9.12 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.14
EY1.04%
EPS(NY)0.1
Fwd EY0.76%
FCF(TTM)-1.58
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS8.81
BVpS8.13
TBVpS1.48
PEG (NY)0.65
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.3% | ||
| ROE | -20.96% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 69.06% | ||
| FCFM | N/A |
ROA(3y)-11.46%
ROA(5y)-9.66%
ROE(3y)-16.36%
ROE(5y)-14.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-2.06%
F-Score5
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 80.83% | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.96 | ||
| Quick Ratio | 1.78 | ||
| Altman-Z | 1.83 |
F-Score5
WACC10.99%
ROIC/WACCN/A
Cap/Depr(3y)77.68%
Cap/Depr(5y)51.8%
Cap/Sales(3y)6.34%
Cap/Sales(5y)4.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)131.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%300%
EPS Next Y147.81%
EPS Next 2Y53.9%
EPS Next 3Y48.99%
EPS Next 5Y40.61%
Revenue 1Y (TTM)12.15%
Revenue growth 3Y5.66%
Revenue growth 5Y0.25%
Sales Q2Q%11.15%
Revenue Next Year11.87%
Revenue Next 2Y8.17%
Revenue Next 3Y8.46%
Revenue Next 5Y8.27%
EBIT growth 1Y42.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year225.57%
EBIT Next 3Y67.26%
EBIT Next 5Y49.52%
FCF growth 1Y12.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.59%
OCF growth 3YN/A
OCF growth 5YN/A